---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021219"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:45:44.537625+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences Q3 net loss narrows to $64.9M, cash $1.19B, ARC-10 amended to compare domvanalimab vs pembro

## Summary
- Q3 revenue $33.6M (up from $9.5M); net loss $64.9M vs $78.0M prior year.
- Cash and securities $1.19B as of Sep 30, 2022, funding operations into 2026.
- ARC-10 Phase 3 amended: domvanalimab+zimberelimab vs pembrolizumab, no chemo arm, OS primary endpoint, n=600.
- ARC-7 topline data on track for Q4 2022; presentation planned at 2023 medical conference.
- Initiated ARC-20 Phase 1/1b for HIF-2a inhibitor AB521 in cancer patients.

## SEC filing metadata
- accession: 0000950170-22-021219
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017022021219/0000950170-22-021219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017022021219/rcus-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021219
- JSON: https://secwatch.observer/filing/0000950170-22-021219.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021219.txt

## Key facts
- Earnings Releases
  Arcus Biosciences, Inc. reported financial results for the three and nine months ended September 30, 2022.
  - Period: the three and nine months ended September 30, 2022
  - Result: reported results
  source text: On November 2, 2022, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000095017022021219/0000950170-22-021219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.